Takeuchi, Ario <br/><br/>
Sunitinib enhances antitumor effects against chemotherapy-resistant             bladder cancer through suppression of ERK1/2 phosphorylation.  [electronic resource] 

 -  International journal of oncology  May 2012 
 - 1691-6 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1791-2423 
<br/><br/><label>Standard No.: </label>10.3892/ijo.2012.1368  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Blotting, Western<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Dose-Response Relationship, Drug<br/>Down-Regulation<br/>Drug Resistance, Neoplasm<br/>Female<br/>Humans<br/>Indoles--pharmacology<br/>Lymphocytes, Tumor-Infiltrating--drug effects<br/>Mice<br/>Mice, Inbred C3H<br/>Mice, Nude<br/>Mitogen-Activated Protein Kinase 1--antagonists & inhibitors<br/>Mitogen-Activated Protein Kinase 3--antagonists & inhibitors<br/>Phosphorylation<br/>Protein Kinase Inhibitors--pharmacology<br/>Pyrroles--pharmacology<br/>Signal Transduction--drug effects<br/>Sunitinib<br/>T-Lymphocytes, Cytotoxic--drug effects<br/>T-Lymphocytes, Regulatory--drug effects<br/>Time Factors<br/>Tumor Burden--drug effects<br/>Urinary Bladder Neoplasms--drug therapy<br/>Xenograft Model Antitumor Assays